Gilead Sciences raised its growth forecast for the year after strong Q3 results, shifting focus from COVID revenues. CEO Daniel O'Day highlighted the company's best quarter, with increased sales in HIV and new business areas like oncology and inflammation. The stock rose 6% on the news.